Generic placeholder image

Current Medicinal Chemistry

Eiditor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery

Author(s): I. Gunaseeli, M. X. Doss, C. Antzelevitch, J. Hescheler and A. Sachinidis

Volume 17 , Issue 8 , 2010

Page: [759 - 766] Pages: 8

DOI: 10.2174/092986710790514480

Price: $58

Abstract

Human induced pluripotent stem (iPS) cells hold great promise for therapy of a number of degenerative diseases such as ischemic heart failure, Parkinsons disease, Alzheimers disease, diabetes mellitus, sickle cell anemia and Huntington disease. They also have the potential to accelerate drug discovery in 3 ways. The first involves the delineation of chemical components for efficient reprogramming of patients blood cells or cells from biopsies, obviating the need for cellular delivery of reprogramming exogenous transgenes, thereby converting hope into reality for patients suffering from degenerative diseases. Patients worldwide stand to benefit from the clinical applicability of iPS cell-based cell replacement therapy for a number of degenerative diseases. The second is the potential for discovering novel drugs in a high throughput manner using patient-specific iPS cell-derived somatic cells possessing the etiology of the specific disease. The third is their suitability for toxicological testing of drugs and environmental factors. This review focuses on these potential applications of iPS cells with special emphasis on recent updates of iPS cell research contributing to the accelerated drug discovery.

Keywords: Induced Pluripotent Stem, Accelerated


Rights & Permissions Print Export Cite as
Related Journals
Related eBooks
Article Metrics
17
Related Articles
© 2020 Bentham Science Publishers